MicroRNA-138 regulates the balance of Th1/Th2 via targeting RUNX3 in psoriasis

Immunology Letters

Volumn 166, Issue 1, 2015, Pages 55-62

  Fu, Dandan ^a   Yu, Wenfa ^a   Li, Min ^a   Wang, Huimin ^a   Liu, Dong ^a   Song, Xiangfeng ^b   Li, Zhanguo ^a   Tian, Zhongwei ^a  

^a The First Affiliated Hospital of Xinxiang Medical University   (China)

^b XINXIANG MEDICAL UNIVERSITY   (China)

Author keywords

CD4^{+< sup> T cells; MicroRNA 138; Psoriasis; RUNX3}

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MICRORNA; MICRORNA 138; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG; MIRN138 MICRORNA, HUMAN; RUNX3 PROTEIN, HUMAN;

ARTICLE; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOREGULATION; MALE; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; PSORIASIS; RUNX3 GENE; TH1 TH2 BALANCE; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; GENETICS; IMMUNOLOGY; TH1 CELL; TH2 CELL;

CORE BINDING FACTOR ALPHA 3 SUBUNIT; FEMALE; HUMANS; MALE; MICRORNAS; PSORIASIS; TH1 CELLS; TH1-TH2 BALANCE; TH2 CELLS;

EID: 84930942522     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2015.05.014     Document Type: Article

References (35)

1. Nestle F.O., Kaplan D.H., Barker J. Psoriasis N. Engl. J. Med. 2009, 361:496-509.
2. Lowes M.A., Bowcock A.M., Krueger J.G. Pathogenesis and therapy of psoriasis. Nature 2007, 445:866-873.
3. Griffiths C.E., Barker J.N. Pathogenesis and clinical features of psoriasis. The Lancet 2007, 370:263-271.
4. Lee E., Trepicchio W.L., Oestreicher J.L., Pittman D., Wang F., Chamian F., et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J. Exp. Med. 2004, 199:125-130.
5. Ghoreschi K., Rocken M. Molecular and cellular basis for designing gene vaccines against inflammatory autoimmune disease. Trends Mol. Med. 2003, 9:331-338.
6. Ghoreschi K., Thomas P., Breit S., Dugas M., Mailhammer R., van Eden W., et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 2003, 9:40-46.
7. Tang H., Jin X., Li Y., Jiang H., Tang X., Yang X., et al. A large-scale screen for coding variants predisposing to psoriasis. Nat. Genet. 2014, 46:45-50.
8. Genetics Garber K. Deep exploration. Nature 2012, 492:S56-S57.
9. Nair R.P., Duffin K.C., Helms C., Ding J., Stuart P.E., Goldgar D., et al. Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways. Nat. Genet. 2009, 41:199-204.
10. Yagi R., Junttila I.S., Wei G., Urban J.F., Zhao K., Paul W.E., et al. The transcription factor GATA3 actively represses RUNX3 protein-regulated production of interferon-gamma. Immunity 2010, 32:507-517.
11. Blyth K., Cameron E.R., Neil J.C. The RUNX genes: gain or loss of function in cancer. Nat. Rev. Cancer 2005, 5:376-387.
12. Brenner O., Levanon D., Negreanu V., Golubkov O., Fainaru O., Woolf E., et al. Loss of Runx3 function in leukocytes is associated with spontaneously developed colitis and gastric mucosal hyperplasia. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16016-16021.
13. Fainaru O., Woolf E., Lotem J., Yarmus M., Brenner O., Goldenberg D., et al. Runx3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO J. 2004, 23:969-979.
14. Naoe Y., Setoguchi R., Akiyama K., Muroi S., Kuroda M., Hatam F., et al. Repression of interleukin-4 in T helper type 1 cells by Runx/Cbf beta binding to the Il4 silencer. J. Exp. Med. 2007, 204:1749-1755.
15. Tsoi L.C., Spain S.L., Knight J., Ellinghaus E., Stuart P.E., Capon F., et al. Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nat. Genet. 2012, 44:1341-1348.
16. Djuretic I.M., Cruz-Guilloty F., Rao A. Regulation of gene expression in peripheral T cells by Runx transcription factors. Adv. Immunol. 2009, 104:1-23.
17. Ambros V., Lee R.C., Lavanway A., Williams P.T., Jewell D. MicroRNAs and other tiny endogenous RNAs in C. elegans. Curr. Biol. 2003, 13:807-818.
18. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
19. Siomi H., Siomi M.C. Posttranscriptional regulation of microRNA biogenesis in animals. Mol Cell. 2010, 38(3):323-332.
20. Sonkoly E., Wei T., Janson P.C., Saaf A., Lundeberg L., Tengvall-Linder M., et al. MicroRNAs: novel regulators involved in the pathogenesis of psoriasis?. PLoS One 2007, 2:e610.
21. Xu N., Brodin P., Wei T., Meisgen F., Eidsmo L., Nagy N., et al. MiR-125b, a microRNA downregulated in psoriasis, modulates keratinocyte proliferation by targeting FGFR2. J. Invest. Dermatol. 2011, 131:1521-1529.
22. Lerman G., Avivi C., Mardoukh C., Barzilai A., Tessone A., Gradus B., et al. MiRNA expression in psoriatic skin: reciprocal regulation of hsa-miR-99a and IGF-1R. PLoS One 2011, 6:e20916.
23. Ichihara A., Jinnin M., Yamane K., Fujisawa A., Sakai K., Masuguchi S., et al. microRNA-mediated keratinocyte hyperproliferation in psoriasis vulgaris. Br. J. Dermatol. 2011, 165:1003-1010.
24. Meisgen F., Xu N., Wei T., Janson P.C., Obad S., Broom O., et al. MiR-21 is up-regulated in psoriasis and suppresses T cell apoptosis. Exp. Dermatol. 2012, 21:312-314.
25. Tomankova T., Petrek M., Gallo J., Kriegova E. MicroRNAs: emerging regulators of immune-mediated diseases. Scand. J. Immunol. 2011, 78:129-141.
26. Zibert J.R., Lovendorf M.B., Litman T., Olsen J., Kaczkowski B., Skov L. MicroRNAs and potential target interactions in psoriasis. J. Dermatol. Sci. 2010, 58:177-185.
27. Jin Y., Chen D., Cabay R.J., Wang A., Crowe D.L., Zhou X. Role of microRNA-138 as a potential tumor suppressor in head and neck squamous cell carcinoma. Int. Rev. Cell Mol. Biol. 2013, 303:357-385.
28. Yeh Y.M., Chuang C.M., Chao K.C., Wang L.H. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int. J. Cancer 2013, 133:867-878.
29. Qiu S., Huang D., Yin D., Li F., Li X., Kung H.F., et al. Suppression of tumorigenicity by microRNA-138 through inhibition of EZH2-CDK4/6-pRb-E2F1 signal loop in glioblastoma multiforme. Biochim. Biophys. Acta 2013, 1832:1697-1707.
30. Kared H., Camous X., Larbi A. T cells and their cytokines in persistent stimulation of the immune system. Curr. Opin. Immunol. 2014, 29:79-85.
31. Ghoreschi K., Weigert C., Rocken M. Immunopathogenesis and role of T cells in psoriasis. Clin. Dermatol. 2007, 25:574-580.
32. Djuretic I.M., Levanon D., Negreanu V., Groner Y., Rao A., Ansel K.M. Transcription factors T-bet and Runx3 cooperate to activate Ifng and silence Il4 in T helper type 1 cells. Nat. Immunol. 2007, 8:145-153.
33. Kohu K., Ohmori H., Wong W.F., Onda D., Wakoh T., Kon S., et al. The Runx3 transcription factor augments Th1 and down-modulates Th2 phenotypes by interacting with and attenuating GATA3. J. Immunol. 2009, 183:7817-7824.
34. Guinea-Viniegra J., Jimenez M., Schonthaler H.B., Navarro R., Delgado Y., Concha-Garzon M.J., et al. Targeting miR-21 to treat psoriasis. Sci. Transl. Med. 2014, 6:225re221.
35. Zhao M., Wang L.T., Liang G.P., Zhang P., Deng X.J., Tang Q., et al. Up-regulation of microRNA-210 induces immune dysfunction via targeting FOXP3 in CD4(+) T cells of psoriasis vulgaris. Clin. Immunol. 2014, 150:22-30.